{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:33:18Z","timestamp":1776454398931,"version":"3.51.2"},"reference-count":52,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.2217\/pgs-2022-0055","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T08:51:32Z","timestamp":1656665492000},"page":"585-596","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Progression of Precision Statin Prescribing for Reduction of Statin-Associated Muscle Symptoms"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-9286","authenticated-orcid":false,"given":"Natasha J","family":"Petry","sequence":"first","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"},{"name":"Department of Pharmacy Practice, North Dakota State University, Fargo, ND\u00a058108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-5415","authenticated-orcid":false,"given":"Jordan F","family":"Baye","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"},{"name":"South Dakota State University, College of Pharmacy & Allied Health Professions, SD\u00a057007, USA"},{"name":"University of South Dakota, Department of Internal Medicine, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Frear","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-5318","authenticated-orcid":false,"given":"Amanda","family":"Massmann","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"},{"name":"University of South Dakota, Department of Internal Medicine, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Schultz","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"},{"name":"University of South Dakota, Department of Internal Medicine, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel Van","family":"Heukelom","sequence":"additional","affiliation":[{"name":"Sanford Health Imagenetics, 1321 W 22nd St, Sioux Falls, SD\u00a057105, USA"},{"name":"University of South Dakota, Department of Internal Medicine, SD\u00a057105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, PRecisiOn Medicine Translational Research (PROMoTeR) Center, Harvard Pilgrim Health Care Institute, Boston, MA\u00a002215, USA"},{"name":"Department of Population Medicine, Harvard Medical School, Boston, MA\u00a002215, USA"},{"name":"Broad Institute of MIT & Harvard, Cambridge, MA\u00a002142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100010"},{"issue":"177","key":"e_1_3_4_4_1","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","author":"Gu Q","year":"2014","unstructured":"Gu Q , Paulose-RamR , BurtVL , KitBK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012. NCHS Data BriefDec(177), 1\u20138 (2014).","journal-title":"NCHS Data Brief"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"11","key":"e_1_3_4_6_1","first-page":"596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett DK","year":"2019","unstructured":"Arnett DK , BlumenthalRS , AlbertMAet al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation140(11), 596\u2013646 (2019).","journal-title":"Circulation"},{"issue":"2","key":"e_1_3_4_7_1","first-page":"108A","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: recommendation statement","volume":"95","year":"2017","unstructured":"Statin use for the primary prevention of cardiovascular disease in adults: recommendation statement. Am. Fam. Physician95(2), 108A\u2013108G (2017).","journal-title":"Am. Fam. Physician"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2001.tb00172.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60716-8"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319380-000000000-00000"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht295"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(97)01147-4"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.05.021"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.125"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13025"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.083030"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2557"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1981"},{"key":"e_1_3_4_20_1","unstructured":"FDA drug safety communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-ongoing-safety-review-high-dose-zocor-simvastatin-and-increased-risk#:\u223c:text=%5B3%2D19%2D2010%5D *%20(simvastatin)%2080%20mg%2C"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60310-8"},{"key":"e_1_3_4_22_1","unstructured":"FDA drug safety communication: new restrictions contraindications and dose limitations of Zocor (simvastatin) to reduce the risk of muscle injury. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_3_4_24_1","unstructured":"USFDA drug safety communication: revised dose limitation for Zocor (simvastatin) when taken with amiodarone. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-dose-limitation-zocor-simvastatin-when-taken-amiodarone"},{"key":"e_1_3_4_25_1","unstructured":"USFDA Table of Pharmacogenetic Associations. www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations#section1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.053"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.125"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1463"},{"key":"e_1_3_4_30_1","unstructured":"Royal Dutch Pharmacists Association \u2013 Dutch Pharmacogenetics Working Group. www.g-standaard.nl\/risicoanalyse\/B0004055.PDF"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi705"},{"issue":"6","key":"e_1_3_4_32_1","first-page":"485","article-title":"Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study","volume":"21","author":"Blackburn D","year":"2005","unstructured":"Blackburn D , DobsonRT , BlackburnJL , WilsonTW , StangMR , SemchukWM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can. J. Cardiol.21(6), 485\u2013488 (2005).","journal-title":"Can. J. Cardiol."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111687"},{"key":"e_1_3_4_34_1","unstructured":"MEPS prescribed medicines file. The top 300 drugs of 2019. https:\/\/clincalc.com\/DrugStats\/Top300Drugs.aspx"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy6020043"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-7-201304020-00004"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201196"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018792702"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.02.011"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12339"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3936"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4680"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774519846852"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1838"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0122-0"},{"issue":"3","key":"e_1_3_4_46_1","first-page":"114","article-title":"Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review","volume":"72","author":"Bo\u017eina N","year":"2021","unstructured":"Bo\u017eina N , GanociL , Simi\u010devi\u0107Let al. Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arh. Hig. Rada. Toksikol.72(3), 114\u2013128 (2021).","journal-title":"Arh. Hig. Rada. Toksikol."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692186"},{"issue":"1","key":"e_1_3_4_48_1","first-page":"40","article-title":"Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial","volume":"6","author":"Adusumalli S","year":"2021","unstructured":"Adusumalli S , WestoverJE , JacobyDSet al. Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial. JAMA Cardiol.6(1), 40\u201348 (2021).","journal-title":"JAMA Cardiol."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2079"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160030"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2111"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000073"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.01.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs-2022-0055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:28:36Z","timestamp":1715992116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs-2022-0055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.2217\/pgs-2022-0055"],"URL":"https:\/\/doi.org\/10.2217\/pgs-2022-0055","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}